← Theravance Biopharma, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Net Income (Loss) Attributable to Parent | ($190.7m) | ($285.4m) | ($215.5m) | ($236.5m) | ($278.0m) | ($199.4m) | $872.1m | ($55.2m) | ($56.4m) | $105.9m | |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | ($278.0m) | ($199.4m) | $872.1m | ($55.2m) | ($56.4m) | $105.9m | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | — | — | — | — | $105.9m | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | — | — | — | — | — | — | ($92.8m) | ($55.2m) | — | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | — | $965.0m | — | — | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | — | — | — | — | — | — | $965.0m | — | — | — | |
| Depreciation, Depletion and Amortization | $3.1m | $4.0m | $3.2m | $6.4m | $6.8m | $5.9m | $3.7m | $2.0m | $1.7m | $1.6m | |
| Depreciation | $2.2m | $2.5m | $3.0m | $3.3m | $3.3m | $3.5m | $2.6m | $1.9m | $1.6m | $1.5m | |
| Amortization of Debt Issuance Costs | — | — | $1.2m | $3.1m | $2.0m | $2.2m | $536k | — | — | — | |
| Deferred Income Tax Expense (Benefit) | $0 | $0 | — | — | — | — | — | $3.2m | ($7.6m) | ($11.5m) | |
| Share-based Payment Arrangement, Noncash Expense | $41.2m | $49.1m | $51.3m | $60.5m | $63.0m | $62.1m | $39.7m | $25.4m | $21.4m | $18.5m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | $3.9m | $8.6m | $9.8m | $3.2m | $9.7m | $9.1m | $3.5m | $2.5m | $2.7m | $4.0m | |
| Share-based Payment Arrangement, Expense | $41.2m | $49.1m | $51.3m | $60.5m | $63.0m | $62.1m | $39.7m | $25.4m | $21.4m | $18.5m | |
| Gain (Loss) on Disposition of Assets | — | — | — | — | — | — | — | $1.2m | — | — | |
| Gain (Loss) on Disposition of Business | — | — | $6.1m | — | — | — | $2.7m | — | — | — | |
| Gain (Loss) on Disposition of Property Plant Equipment | — | — | $17k | $5k | $64k | ($39k) | $8k | ($1.4m) | ($34k) | ($35k) | |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | ($15.5m) | — | ($3.0m) | — | — | — | |
| Income (Loss) from Equity Method Investments | — | — | $11.2m | $33.7m | $68.4m | $104.0m | — | — | — | — | |
| Income Tax Expense (Benefit) | $10.1m | $13.7m | ($10.6m) | ($5.2m) | ($8.5m) | ($151k) | $9k | $5.9m | $11.8m | $23.4m | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $2.5m | $2.5m | |
| Other Nonoperating Income (Expense) | $1.3m | $5.0m | $12.0m | $8.4m | $2.8m | $1.1m | $8.5m | $9.1m | $4.9m | $10.2m | |
| Changes in operating assets and liabilities: | |||||||||||
| Additional Financial Items | |||||||||||
| Increase (Decrease) in Accounts Receivable | ($1.3m) | $1.6m | ($1.6m) | ($620k) | — | — | — | — | — | — | |
| Increase (Decrease) in Inventories | $3.2m | $7.3m | $1.6m | — | — | — | — | — | — | — | |
| Increase (Decrease) in Accounts Payable | ($16.4m) | $3.8m | $3.6m | ($4.3m) | $3.7m | ($3.5m) | ($1.6m) | $6k | $750k | $326k | |
| Proceeds from Stock Options Exercised | $4.4m | $6.2m | $1.4m | $3.1m | $1.4m | $5k | — | — | — | $766k | |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously Recorded | — | — | — | — | — | — | — | — | — | $0 | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | — | ($900k) | $900k | $60k | ($100k) | ($100k) | |
| Inventory Write-down | $303k | $740k | — | — | — | — | — | — | — | — | |
| Operating Expenses | $229.1m | $275.5m | $299.1m | $325.3m | $369.6m | $313.1m | $143.3m | $113.5m | $111.3m | $111.1m | |
| Proceeds from Contributions from Affiliates | $0 | — | — | — | — | — | — | — | — | — | |
| Proceeds from Contributions from Parent | $0 | — | — | — | — | — | — | — | — | — | |
| Net Cash Provided by (Used in) Operating Activities | ($99.0m) | ($201.1m) | ($112.9m) | ($238.2m) | ($250.4m) | ($207.9m) | ($187.0m) | ($27.0m) | ($11.5m) | $238.5m | |
| Cash flows from investing activities: | |||||||||||
| Payments to Acquire Property, Plant, and Equipment | $2.1m | $2.4m | $7.2m | $3.2m | $6.6m | $3.4m | $572k | $2.5m | $332k | $42k | |
| Net Cash Provided by (Used in) Investing Activities | ($148.2m) | ($56.3m) | $176.7m | ($83.1m) | $10.7m | $124.5m | $1.2b | ($32.7m) | $12.3m | ($105.3m) | |
| Cash flows from financing activities: | |||||||||||
| Proceeds from Issuance of Long-term Debt | — | — | — | — | $380.0m | — | — | — | — | — | |
| Proceeds from Issuance of Common Stock | $253.0m | $0 | — | — | $139.9m | $108.2m | — | — | $99k | $20k | |
| Payments for Repurchase of Common Stock | — | — | — | — | — | — | $128.8m | $197.1m | $445k | — | |
| Net Cash Provided by (Used in) Financing Activities | $479.2m | $1.7m | $225.2m | $1.3m | $263.1m | $91.9m | ($758.8m) | ($198.9m) | ($2.5m) | ($3.2m) | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | $289.0m | ($320.0m) | $23.4m | $8.5m | $208.2m | ($258.6m) | ($1.7m) | $130.0m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $232.0m | ($255.7m) | $378.9m | $58.9m | $82.3m | $90.8m | $299.0m | $40.4m | $38.6m | $168.6m | |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | $7.5m | $7.5m | $26.2m | $24.0m | $39.0m | $22.2m | — | — | — | |
| Income Taxes Paid, Net | ($9.5m) | $4.9m | ($7.3m) | $22k | $14k | ($4.1m) | $118.0m | $24k | $109k | $27.9m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.